Metropolis Healthcare Limited , India's second-largest diagnostic chain, has reported a robust 23% year-on-year revenue growth to ₹429.00 crore for the quarter ended September 30, 2025 (Q2 FY26). The company's EBITDA grew by 19% to ₹109.00 crore, while profit after tax (PAT) increased by 13% to ₹53.00 crore compared to the same quarter last year.

Key Financial Highlights

Business Segment Performance

The company's growth was driven by strong performance across its business segments:

• B2C Revenue: ₹240.00 crore (+16% YoY)
• B2B Revenue: ₹189.00 crore (+33% YoY)
• TruHealth (wellness) Revenue: +24% YoY
• Specialty Testing Revenue: +33% YoY

Geographical Expansion and Acquisitions

Metropolis Healthcare has been actively expanding its presence across India:

• Revenue contribution from North India increased to 19% (from 17% in Q1 FY26)
• Tier III cities registered 13% revenue growth

The company's recent acquisitions have started showing positive results:

• Core Diagnostics achieved positive PAT and high single-digit EBITDA margins within two quarters of acquisition
• DAPIC (Dehradun) and Scientific Pathology (Agra) continue to outperform the company's average margin levels

Strategic Initiatives

Metropolis Healthcare is focusing on several key areas to drive growth:

1. Expanding its test menu, with a focus on high-value specialty and preventive health tests
2. Strengthening its presence in Tier II and Tier III markets
3. Enhancing digital capabilities to improve customer experience and operational efficiency
4. Pursuing strategic acquisitions to enter new geographies and expand service offerings

Management Commentary

Ameera Shah, Promoter and Executive Chairperson of Metropolis Healthcare, stated, "We've demonstrated that consistent growth and quality can go hand in hand. The swift turnaround of Core Diagnostics and the strong performance of our recent acquisitions in Dehradun and Agra reaffirm the strength of our integration strategy and our ability to create sustainable value through local excellence."

Surendran Chemmenkotil, Managing Director, added, "We delivered consistent results this quarter, in line with our guidance, even as lower incidence of vector-borne diseases impacted seasonal demand. Our focus on execution excellence, productivity enhancement, and operational optimization helped sustain growth momentum and deliver year-on-year margin expansion in H1."

Dividend Declaration

The Board of Directors has approved an interim dividend of ₹4.00 per equity share (face value of ₹2.00 each) for the financial year 2025-26.

Outlook

Metropolis Healthcare remains confident in achieving its stated growth and profitability targets for the rest of the year. The company continues to focus on deepening its presence across 750+ towns, with sharper penetration in Tier 2 and Tier 3 markets, supported by a strong product portfolio and productivity-enhancing initiatives in the network.

As Metropolis Healthcare continues to expand its footprint and enhance its service offerings, it is well-positioned to capitalize on the growing demand for quality diagnostic services in India.

Metropolis Healthcare , a prominent player in the Indian healthcare diagnostics sector, has announced a dividend and reported financial results while also taking significant steps towards employee retention and motivation.

Dividend Declaration and Financial Performance

Metropolis Healthcare has declared a dividend of Rs 4 per share. The company reported a Q2 EBITDA of Rs 1.10 billion, showing growth compared to Rs 899.00 million in the same period last year. However, the Q2 EBITDA margin slightly decreased to 25.22% from 25.70% in the previous year.

Stock Benefit Details

The company's Nomination and Remuneration Committee has approved the grant of stock benefits to eligible employees under multiple plans, as disclosed in a recent regulatory filing. The company has authorized the following grants:

Vesting and Exercise Details

For all three plans, the company has set the following terms:

• Minimum Vesting Period: 1 year
• Maximum Vesting Period: Up to 4 years
• Exercise Period: Maximum of 5 years from the date of vesting

This structured approach to vesting and exercise periods aims to promote long-term employee engagement and align staff interests with the company's performance.

Regulatory Compliance

Metropolis Healthcare has confirmed that all these schemes are in compliance with the Securities and Exchange Board of India (Share Based Employee Benefits) Regulations, 2021. This adherence ensures transparency and fairness in the implementation of these stock benefit plans.

Strategic Implications

The introduction of these stock benefit plans, particularly the substantial grant under the Employees Stock Options Plan 2025, suggests Metropolis Healthcare's commitment to:

1. Attracting and retaining top talent in the competitive healthcare sector
2. Aligning employee interests with long-term company growth
3. Fostering a sense of ownership among staff members

By offering a mix of restricted stock units and stock options, Metropolis Healthcare is providing its employees with both immediate value and potential for future gains tied to the company's performance.

The company's decision to grant these benefits comes at a time when the healthcare sector in India is experiencing rapid growth and transformation. Such employee-centric initiatives may help Metropolis Healthcare maintain its competitive edge in the market.

As the diagnostic healthcare landscape continues to evolve, Metropolis Healthcare's move to strengthen its employee incentive structure, coupled with its financial performance and shareholder returns, could play a crucial role in its future success and market position.